Aged 18 years or older, male or female.
Systolic heart failure with New York Heart Association (NYHA) class II-III.
Left ventricular ejection fraction (LVEF) less than 40% by echocardiography during screening and randomization.
SCH (TSH: upper limits of normal (ULN) -10mIU/L, and FT4 level within reference range).
Having received standard HF therapy for at least 2 weeks, having reached target dose or max tolerable dose.
Provided informed consent.
